Medicine and Dentistry
Heart Failure
100%
Patient
55%
Inpatient
46%
Ejection Fraction
25%
Association
25%
Therapeutic Procedure
23%
Cardiovascular System
21%
Influenza Vaccination
21%
Mortality
18%
Cardiovascular Disease
15%
Heart Failure with Preserved Ejection Fraction
14%
Heart Failure
13%
COVID-19
12%
Combination Therapy
12%
Death
12%
Influenza Vaccine
12%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Valsartan
9%
Woman
9%
Influenza
9%
Hazard Ratio
9%
Spironolactone
9%
Age
9%
Atherosclerosis
8%
Joint
8%
Morbidity
8%
Heart Failure with Reduced Ejection Fraction
8%
Incidence
7%
Cardiovascular Risk
7%
Diuretic Agent
7%
Analysis
7%
Drug Therapy
7%
Introspection
7%
Diabetes
6%
Diabetes Mellitus
6%
Clinical Trial
6%
Placebo
6%
Health
5%
Loop Diuretic Agent
5%
Man
5%
Kidney Function
5%
Adverse Event
5%
Mineralocorticoid Antagonist
5%
Cardiology
5%
Meta-Analysis
5%
Predictor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
75%
Valsartan/Sacubitril
19%
Dapagliflozin
17%
Influenza
15%
Mortality
13%
Heart Failure with Reduced Ejection Fraction
12%
Spironolactone
12%
Heart Failure with Preserved Ejection Fraction
9%
Enalapril
8%
Incidence
8%
Death
8%
Mineralocorticoid Antagonist
8%
Live Attenuated Influenza Vaccine
7%
Cardiovascular Disease
7%
Cardiovascular Risk
6%
Dipeptidyl Carboxypeptidase Inhibitor
6%
Clinical Trial
6%
Placebo
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Morbidity
6%
Peptide Hydrolase Inhibitor
5%
Diseases
5%
Atherosclerosis
5%
Pharmacology
5%
Nursing and Health Professions
Heart Failure
46%
Patient
20%
Practice Guideline
11%
Cardiovascular Disease
8%
Inpatient
8%
Influenza Vaccination
7%
Heart Ejection Fraction
7%
Vaccination Policy
6%
Immunization
6%
Mortality
6%
Hospitalization
6%
Drug Therapy
5%
Diseases
5%
Combination Therapy
5%
